公开(公告)号：EP1478354A4

公开(公告)日：2008-09-24

申请号：EP03707462

申请日：2003-01-21

Applicant: GENZYME CORP ,  UNIV HEALTH NETWORK

Inventor： KESHAVJEE SHAF ,  ST GEORGE JUDITH A ,  LIU MINGYAO

IPC: A61K45/00 ,  A61K31/00 ,  A61K31/194 ,  A61K31/7004 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/22 ,  A61K38/30 ,  A61K38/31 ,  A61K48/00 ,  A61P1/16 ,  A61P9/00 ,  A61P11/00 ,  A61P13/12 ,  A61P37/06 ,  C07K14/495 ,  C07K14/71 ,  A61K31/70

CPC classification number: C07K14/71 ,  A61K31/00 ,  A61K31/194 ,  A61K31/7004 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/495 ,  C12N2799/022

Abstract: Effective use of a TGF-β antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-β antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-β-mediated fibroproliferation is a characteristic. Expression in situ of a TGF-β antagonist in the form of a recombinant receptor, i.e., TGF-β type III receptor (TGFBIIIR) showed prevention of bronchiolitis obliterans in comparison to untreated controls in a rat lung transplant model. This provides an effective method for preventing or inhibiting chronic rejection of transplant organs such as lung, kidney, liver and hear in vertebrate hosts including human hosts.

公开(公告)号：CA2473829A1

公开(公告)日：2003-07-31

申请号：CA2473829

申请日：2003-01-21

Applicant: GENZYME CORP ,  UNIV HEALTH NETWORK

Inventor： LIU MINGYAO ,  ST GEORGE JUDITH A ,  KESHAVJEE SHAF

IPC: A61K45/00 ,  A61K31/00 ,  A61K31/194 ,  A61K31/7004 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/22 ,  A61K38/30 ,  A61K38/31 ,  A61K48/00 ,  A61P1/16 ,  A61P9/00 ,  A61P11/00 ,  A61P13/12 ,  A61P37/06 ,  C07K14/495 ,  C07K14/71 ,  A61K31/70

Abstract: Effective use of a TGF-.beta. antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-.beta. antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-.beta.-mediated fibroproliferation is a characteristic. Expression in situ of a TGF-.beta. antagonist in the form of a recombinant receptor, i.e., TGF-.beta. type III receptor (TGFBIIIR) showed prevention of bronchiolitis obliterans in comparison to untreated controls in a rat lung transplant model. This provides an effective method for preventing or inhibiting chronic rejection of transplant organs such as lung, kidney, liver and hear in vertebrate hosts including human hosts.